Next Article in Journal
TupA: A Tungstate Binding Protein in the Periplasm of Desulfovibrio alaskensis G20
Next Article in Special Issue
TRPV1 Activation Exacerbates Hypoxia/Reoxygenation-Induced Apoptosis in H9C2 Cells via Calcium Overload and Mitochondrial Dysfunction
Previous Article in Journal
Paeonol Suppresses Chondrosarcoma Metastasis through Up-Regulation of miR-141 by Modulating PKCδ and c-Src Signaling Pathway
Previous Article in Special Issue
Endothelial Dysfunction in Chronic Inflammatory Diseases
Review

Restoration of Asymmetric Dimethylarginine–Nitric Oxide Balance to Prevent the Development of Hypertension

by 1,2 and 1,3,*
1
Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
2
Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
3
Department of Traditional Chinese Medicine, Chang Gung University, Taoyuan 333, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(7), 11773-11782; https://doi.org/10.3390/ijms150711773
Received: 27 May 2014 / Revised: 24 June 2014 / Accepted: 27 June 2014 / Published: 2 July 2014
(This article belongs to the Special Issue Oxidative Stress in Cardiovascular Disease 2015)
Despite the use of extensive antihypertensive therapy in patients with hypertension, little attention has been paid to early identification and intervention of individuals at risk for developing hypertension. The imbalance between nitric oxide (NO) and reactive oxygen species (ROS) resulting in oxidative stress has been implicated in the pathophysiology of hypertension. NO deficiency can precede the development of hypertension. Asymmetric dimethylarginine (ADMA) can inhibit nitric oxide synthase (NOS) and regulate local NO/ROS balance. Emerging evidence supports the hypothesis that ADMA-induced NO–ROS imbalance is involved in the development and progression of hypertension. Thus, this review summarizes recent experimental approaches to restore ADMA–NO balance in order to prevent the development of hypertension. Since hypertension might originate in early life, we also discuss the putative role of the ADMA–NO pathway in programmed hypertension. Better understanding of manipulations of the ADMA–NO pathway prior to hypertension in favor of NO will pave the way for the development of more effective medicine for the treatment prehypertension and programmed hypertension. However, more studies are needed to confirm the clinical benefit of these interventions. View Full-Text
Keywords: asymmetric dimethylarginine; nitric oxide; hypertension; prehypertension; programmed hypertension asymmetric dimethylarginine; nitric oxide; hypertension; prehypertension; programmed hypertension
Show Figures

Graphical abstract

MDPI and ACS Style

Tain, Y.-L.; Huang, L.-T. Restoration of Asymmetric Dimethylarginine–Nitric Oxide Balance to Prevent the Development of Hypertension. Int. J. Mol. Sci. 2014, 15, 11773-11782. https://doi.org/10.3390/ijms150711773

AMA Style

Tain Y-L, Huang L-T. Restoration of Asymmetric Dimethylarginine–Nitric Oxide Balance to Prevent the Development of Hypertension. International Journal of Molecular Sciences. 2014; 15(7):11773-11782. https://doi.org/10.3390/ijms150711773

Chicago/Turabian Style

Tain, You-Lin, and Li-Tung Huang. 2014. "Restoration of Asymmetric Dimethylarginine–Nitric Oxide Balance to Prevent the Development of Hypertension" International Journal of Molecular Sciences 15, no. 7: 11773-11782. https://doi.org/10.3390/ijms150711773

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop